{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:40:09Z","timestamp":1783528809686,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of Xiangshao granules in improving clinical symptoms and regulating serum hormone levels in patients with menopausal syndrome (MPS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was developed according to the PRISMA 2020 guidelines. Eight databases including PubMed, Web of Science, The Cochrane Library, Embase, CNKI, CBM, Wanfang Database, and VIP database were searched for randomized controlled trials (RCTs) of Xiangshao Granules in the treatment of MPS. The search time was from the listing of Xiangshao Granules (2005) to September 1, 2024. Xiangshao granule was used in experimental group. The control group was treated with placebo, other Chinese patent medicine, or conventional western medicine. The treatment period should be at least 4 weeks. RevMan5.4 was used for bias risk assessment and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13 randomized controlled trials with 1637 participants were included. The meta-analysis showed that there was statistical significance between Xiangshao granules and control group in improving clinical symptoms (P&amp;lt;0.05). Xiangshao granules could improve the total response rate (OR= 2.78, 95%CI[1.65, 4,68], P&amp;lt;0.05) and reduce Kupperman score (MD=-1.23, 95%CI[-2.10,-0.36], P&amp;lt;0.05). In addition, Xiangshao granules also decreased HAMD score (MD= -2.80, 95%CI[-3.54, -2.07], P&amp;lt;0.05) and HAMA score (MD=-2.52, 95%CI[-3.00,-2.04], P&amp;lt;0.05). In terms of serum hormone levels, there was no significant difference in serum FSH levels between Xiangshao granule group and control group(SMD=-0.81, 95%CI[-2.03, 0.41], P= 0.19). However, the regulating effect of Xiangshao granules on serum LH and E2 levels was statistically significant compared with the control group (P&amp;lt;0.05). The results of subgroup analysis showed that Xiangshao granules were better than other Chinese patent medicines in reducing serum LH levels (SMD=-1.20, 95%C[-1.66,-0.73]I, P&amp;lt;0.05). Xiangshao granules were superior to other Chinese patent medicines or placebo in increasing serum E2 levels (SMD=5.28, 95%CI[4.90, 5.66], P&amp;lt;0.05) (SMD=2.00, 95%CI[1.10, 2.90], P&amp;lt;0.05). Furthermore, the combined use of western medicine and Xiangshao granules was better than HRT or SSRIs alone in reducing serum LH level and increasing serum E2 level (P&amp;lt;0.05). In terms of safety, there was no significant difference in the incidence of adverse reactions among all groups (OR= 1.28, 95%CI[0.80, 2.05], P = 0.31).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Xiangshao Granules can effectively relieve the clinical symptoms of MPS patients, improve the scores of anxiety and depression and regulate the level of serum estrogen, with good safety, and is an ideal treatment plan. In the future, multi-center and large sample randomized controlled trials can be conducted for more key clinical indicators to comprehensively analyze the clinical efficacy and applicability of Xiangshao granules in the treatment of MPS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/<\/jats:uri>, identifier CRD42023405228.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1546200","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:13:14Z","timestamp":1740719594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Xiangshao granules on clinical symptoms and serum hormone levels of menopausal syndrome: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Xing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisha","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoujin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoujen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeayin","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60346-3","article-title":"Menopause","volume":"371","author":"Nelson","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.09.016","article-title":"The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms","volume":"58","author":"Kumari","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12905-017-0484-x","article-title":"Prevalence and severity of menopause symptoms among perimenopausal and postmenopausal women aged 30-49 years in Gulele sub-city of Addis Ababa, Ethiopia","volume":"17","author":"Yisma","year":"2017","journal-title":"BMC Womens Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e4466","DOI":"10.1097\/MD.0000000000004466","article-title":"Perimenopausal syndrome and mood disorders in perimenopause: prevalence, severity, relationships, and risk factors","volume":"95","author":"Li","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-9081.2018.06.007","article-title":"Chinese guidelines for menopausal management and menopausal hormone therapy (2018)","volume":"9","author":"Xie","year":"2018","journal-title":"Chin J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.16484\/j.cnki.issn2095-8803.2016.02.012","article-title":"Guidelines for the care of menopausal women (2015)","volume":"3","year":"2016","journal-title":"J Pract Gynecol Endocrine J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00117","article-title":"NIH State-of-the-Science Conference Statement on the management of menopause-related symptoms","volume":"21","year":"2005","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD002978","DOI":"10.1002\/14651858.CD002978.pub2","article-title":"Oral estrogen and combined estrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2012-100508","article-title":"Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies","volume":"39","author":"Shapiro","year":"2013","journal-title":"J Fam Plann Reprod Health Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2005.11.003","article-title":"Alternatives to hormone replacement therapy: a multi-method study of women\u2019s experiences","volume":"14","author":"Wathen","year":"2006","journal-title":"Complement Ther Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.11675\/j.issn.0253-4304.2020.11.12","article-title":"Effect of Xiangshao Granules combined with Kuntai capsule in the treatment of premenstrual syndrome and its effect on serum neurotransmitters","volume":"42","author":"Zhao","year":"2020","journal-title":"Guangxi Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3760\/cma.j.issn.0529-567x.2013.10.018","article-title":"Clinical Practice Guideline for menopausal management and hormone replacement therapy (2012 edition)","volume":"48","year":"2013","journal-title":"Chin J Obstet Gynecol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20240428.501","article-title":"Expert consensus on clinical application of Xiangshao Granules","volume":"49","year":"2024","journal-title":"Chin J Appl Gynecol Obstet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13048-024-01531-z","article-title":"A preliminary study on the effects of Xiang Shao granules on reproductive endocrinology in drugged ovariectomised rats","volume":"17","author":"Jia","year":"2024","journal-title":"J Ovarian Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7501\/j.issn.1674-5515.2021.08.020","article-title":"Clinical study of Xiangshao Granules combined with estradiol tablets\/estradiol and dydrogesterone tablets in the treatment of the perimenopausal syndrome","volume":"36","author":"Geng","year":"2021","journal-title":"Modern Med Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.15975\/j.cnki.gsyy.2013.09.006","article-title":"Clinical observation of Xiangshao Granules in the treatment of MPS","volume":"32","author":"Gou","year":"2013","journal-title":"Gansu Med"},{"key":"B19","article-title":"Efficacy analysis of Xiangshao Granules in the treatment of female MPS","volume":"12","author":"Wu","year":"2014","journal-title":"Guide to Chin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.15887\/j.cnki.13-1389\/r.2016.03.088","article-title":"Quality control and clinical research progress of Xiangshao granules","volume":"9","author":"Ye","year":"2016","journal-title":"J Clin Rational Drug Use"},{"key":"B21","article-title":"Effect of xiangshao granules in the treatment of MPS","volume":"14","author":"Cai","year":"2016","journal-title":"J Contemp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"142,144","DOI":"10.19613\/j.cnki.1671-3141.2019.85.090","article-title":"Clinical observation of Xiangshao Granules in the treatment of MPS","volume":"19","author":"Liu","year":"2019","journal-title":"World Latest Medical Information Abstract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2020.1820476","article-title":"Xiangshao Granules can relieve emotional symptoms in menopausal women: a randomized controlled trial","volume":"24","author":"Chen","year":"2021","journal-title":"Climacteric"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.19829\/j.zgfybj.issn.1001-4411.2021.21.058","article-title":"A randomized, double-blind, placebo-controlled clinical trial of Xiangshao Granules in the treatment of mood disorders in perimenopausal women","volume":"4","author":"Xu","year":"2021","journal-title":"China\u2019s Maternity Child Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14163\/j.cnki.11-5547\/r.2022.07.002","article-title":"Effect of Chinese medicine Xiangshao Granules on perimenopausal syndrome and its influence on ovarian function","volume":"17","author":"Li","year":"2021","journal-title":"Chin J Pract Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.16484\/j.cnki.issn2095-8803.2021.11.010","article-title":"Effects of oral Xiangshao granules on perimenopausal symptoms and ovarian function after laparoscopic hysterectomy","volume":"8","author":"Mao","year":"2021","journal-title":"Pract Gynecol Endocrine Electronic J"},{"key":"B27","article-title":"Curative effect of Xiangshao granules on female perimenopausal syndrome","volume":"10","author":"Liu","year":"2021","journal-title":"Medicine and Health"},{"key":"B28","article-title":"Clinical observation of Xiangshao Granules combined with paroxetine in the treatment of perimenopausal depression with sleep disorders","volume":"39","author":"Wu","year":"2023","journal-title":"J Pract Chin Med"},{"key":"B29","article-title":"Effect of Xiangshao granules combined with Citalopram hydrobromide on menopausal depression in women","volume":"35","author":"Bao","year":"2023","journal-title":"J Jiangxi Univ Traditional Chin Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B31","first-page":"59","article-title":"The third edition of Chinese Classification and Diagnosis Criteria for Mental Disorders","year":"2001","journal-title":"Chin J Psychiatry"},{"key":"B32","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing the risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1546200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:13:32Z","timestamp":1740719612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1546200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":32,"alternative-id":["10.3389\/fendo.2025.1546200"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1546200","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1546200"}}